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Abstract
Background: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodeficiency
virus (HIV) infection have demonstrated variable efficacy in men and women prompting assessment of variation in drug
concentration as an explanation. Knowledge of tenofovir concentration and its active form, tenofovir diphosphate, at the
putative vaginal and rectal site of action and its relationship to concentrations at multiple other anatomic locations may
provide key information for both interpreting PrEP study outcomes and planning future PrEP drug development.
Objective: MTN-001 was designed to directly compare oral to vaginal steady-state tenofovir pharmacokinetics in blood,
vaginal tissue, and vaginal and rectal fluid in a paired cross-over design.
Methods and Findings: We enrolled 144 HIV-uninfected women at 4 US and 3 African clinical research sites in an open
label, 3-period crossover study of three different daily tenofovir regimens, each for 6 weeks (oral 300 mg tenofovir
disoproxil fumarate, vaginal 1% tenofovir gel [40 mg], or both). Serum concentrations after vaginal dosing were 56-fold
lower than after oral dosing (p,0.001). Vaginal tissue tenofovir diphosphate was quantifiable in $90% of women with
vaginal dosing and only 19% of women with oral dosing. Vaginal tissue tenofovir diphosphate was $130-fold higher with
vaginal compared to oral dosing (p,0.001). Rectal fluid tenofovir concentrations in vaginal dosing periods were higher than
concentrations measured in the oral only dosing period (p,0.03).
Conclusions: Compared to oral dosing, vaginal dosing achieved much lower serum concentrations and much higher vaginal
tissue concentrations. Even allowing for 100-fold concentration differences due to poor adherence or less frequent
prescribed dosing, vaginal dosing of tenofovir should provide higher active site concentrations and theoretically greater
PrEP efficacy than oral dosing; randomized topical dosing PrEP trials to the contrary indicates that factors beyond tenofovir’s
antiviral effect substantially influence PrEP efficacy.
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Introduction
Four recently completed clinical trials demonstrated the
effectiveness of both vaginal and oral tenofovir (TFV)-containing
regimens as pre-exposure prophylaxis (PrEP) to prevent HIV
infection in susceptible men, women, and partners of HIV-infected
individuals [1,2,3,4]. Relative risk reduction varied widely: 39% in
women using vaginal TFV gel before and after sex (CAPRISA
004) [1], 44% in men who have sex with men (MSM) using daily
oral TFV disoproxil fumarate (TDF)/emtricitabine (FTC) (iPrEX)
[2], 62% or 75% with daily use of TDF/FTC in men and women
whose heterosexual partner(s)’ HIV-1 serostatus was either
unknown (CDC TDF2) [4] or known positive (Partner’s PrEP)
[3], respectively. In contrast, all or part of two other studies of
women using daily TDF/FTC tablets (FEM-PrEP) [5], daily TDF
tablets (VOICE) [6], or daily TFV vaginal gel (VOICE) [7] were
stopped early for futility.
Knowledge of active drug at the site of action, arguably the
vaginal tissue in women, linked with seroconversion events in these
clinical trials could provide critical information for interpreting
outcomes and guiding dose and frequency decisions for future
clinical trials by indicating the critical concentration needed to
prevent infection. To date, none of these clinical trials have
reported the concentration of active drug in the site of action due
largely to logistical constraints in these large clinical studies.
Drug concentration at anatomic sites more distant from the
rectal or vaginal mucosal tissue, however, was associated with HIV
seroconversion events in all trials where pharmacokinetic (PK)
results have been reported. Detecting drug in plasma or peripheral
blood mononuclear cells (PBMCs) was associated with significantly
higher relative risk reduction when compared to the primary
modified intent-to-treat analysis in iPrEX (92% vs. 44%) and
Partner’s PrEP (86% vs. 67% for TDF, 90% vs. 75% for TDF/
FTC)(all p values ,0.05) [2,8]. In CAPRISA 004, tenofovir
concentration in cervicovaginal fluid greater than 1,000 ng/mL
was associated with increased efficacy [9]. Bridging data that
connects drug concentrations in these more distant sites – blood
and cervicovaginal fluid - to vaginal and rectal tissue in association
with seroconversion events is needed to identify target drug
concentrations in the mucosal tissue sites associated with
protection of HIV infection. This knowledge would be of
substantial benefit to future PrEP drug development.
We report the results of such a PK bridging study, MTN-001,
which directly compares vaginal TFV gel and oral tenofovir
disoproxil fumarate (TDF) tablets in a cross-over design thus
removing inter-individual variation to provide more precise paired
comparisons. We measured steady-state pharmacokinetics of TFV
and its active form, TFV diphosphate (TFV-DP), in blood, vaginal
tissue, vaginal lumen, and rectal lumen to better understand
concentrations in a wide range of anatomic locations after different
routes of dosing. The substantially different TFV concentrations in
blood and tissue after oral compared to vaginal dosing was
successfully described.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
As this research involved human subjects, written informed
consent was obtained from all research participants and the
clinical investigation was conducted according to the principles
expressed in the Declaration of Helsinki. The study was conducted
following US National Institutes of Health and local IRB approval
at seven clinical sites: Umkomaas and Botha’s Hill, Durban, South
Africa; Makerere University-Johns Hopkins University Research
Collaboration, Kampala, Uganda; Case Western Reserve Uni-
versity in Cleveland, OH, USA; University of Pittsburgh,
Pittsburgh, PA, USA; University of Alabama at Birmingham,
Birmingham, AL, USA; Bronx-Lebanon Hospital Center, New
York City, NY, USA. The study is registered at ClinicalTrials.gov
(Identifier NCT00592124). The full protocol is available online:
http://www.mtnstopshiv.org.
Study Schema
MTN-001 was a 21-week, phase 2, open-label, crossover study
in which all participants were assigned to a randomized sequence
of daily tenofovir orally, vaginally, or both orally and vaginally in
three 6-week study periods, separated by one-week washouts
between study periods (Table 1). Adherence to and acceptability of
various routes of TFV administration was also assessed, but is
reported in detail elsewhere along with supplemental PK data used
for adherence assessment [10]. Microbicide Trial Network (MTN)
laboratories at The Johns Hopkins University and the University
of Pittsburgh performed drug assays and flow cytometric analyses,
respectively. The clinical phase of the study began in June 2008
Table 1. MTN-001 Study Schema.
N Period 1 Washout Period 2 Washout Period 3
6 weeks 1 week 6 weeks 1 week 6 week
Sequence A 24 Oral – Vaginal – Oral+Vaginal
Sequence B 24 Vaginal – Oral – Oral+Vaginal
Sequence C 24 Oral+Vaginal – Oral – Vaginal
Sequence D 24 Oral+Vaginal – Vaginal – Oral
Sequence E 24 Oral – Oral+Vaginal – Vaginal
Sequence F 24 Vaginal – Oral+Vaginal – Oral
Formulations: Oral, 300 mg tenofovir disoproxil fumarate; Vaginal, 1% tenofovir gel.
Sampling occurs at the 3-week mid-point (blood only) and 6-week end of period visit (blood, PBMC, vaginal biopsy [intensive sites], vaginal fluid, and rectal fluid [Bronx-
Lebanon site]).
Number of samples at each visit varied between intensive (US) and non-intensive (African) clinical sites.
doi:10.1371/journal.pone.0055013.t001
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and finished in July 2010 when the final enrolled participant
completed all study visits.
Study Participants
Women were recruited through clinical research sites and
community outreach. After the nature and possible consequences
of the study was explained, all participants provided written
informed consent prior to screening and study enrollment. Eligible
participants were women aged 18–45 years, HIV-uninfected,
sexually active, non-pregnant, and using an effective method of
contraception. Participant self-identified race/ethnicity was re-
corded. Major exclusion criteria included: pregnancy, significant
blood chemistry or hematology laboratory abnormalities, hepatitis
B surface antigen positivity, clinically apparent gynecological
abnormality, sexually transmitted or urinary tract infections
requiring treatment, recent use or intended use of specific forms
of contraception (diaphragm, vaginal ring, spermicide) or use of
non-study vaginal products.
Participants evaluable for the final analysis included women
who were dispensed study product and returned to report on
product use at least once in each of the three study periods.
Study Procedures
Eligible research participants were randomized equally to one of
6 sequences of oral, vaginal, and combination dosing of study drug
for each of the three 6-week periods. Randomization, conducted
by the data coordinating center, was stratified by site. Blocks of
size 6 and 12 were chosen randomly to distribute the six treatment
sequences. The uniform distribution was used to generate the
random assignments. Sites received sealed, numbered randomi-
zation envelopes that were assigned in sequential order to each
participant at the time of enrollment. The randomized dosing
sequence was revealed to the study team and research participant
after receipt of randomization envelope. No drug was taken during
a one week washout between study periods (Table 1). Tenofovir
disoproxil fumarate tablets (VireadTM), 300 mg, were provided
by Gilead Sciences (Foster City, CA). Tenofovir gel was provided
by CONRAD (Arlington, VA). Participants were instructed to take
study product(s) once daily before bedtime or the longest period of
rest.
Study visits took place at enrollment, at the 3-week midpoint,
and again at the end of each six-week study period, and after the
final one-week washout period for a total duration of 21 weeks.
The PK sampling took place at the 3-week mid-period and 6-week
end-of-period visits. Blood for serum and PBMCs was collected at
the mid-period visits. More intensive end-of-period sampling
differed by clinical research site. At the African sites, blood (serum,
PBMCs) was collected prior to a dose in clinic and during one
specified randomized time interval (1–3, 3–5, or 5–7 hours post
dose) and repeated at the same time in each study period.
Cervicovaginal lavage (CVL) fluid was collected in the same
specified time interval as the blood collection. At the US sites,
more intensive sampling was performed, with blood (serum,
PBMCs) collected pre-dose and 1, 2, 4, 6, and 8 hours after dosing
in clinic for each study period. In addition, CVL, endocervical
cytobrush sampling (ECC), and 2 vaginal tissue biopsies were
collected from each participant in each study period at one
randomly assigned time (pre-dose, 2, 4, and 6 hours after dosing).
US sites collected PBMCs for flow cytometry assessment at end-of-
period visits. At the Bronx-Lebanon site, rectal sponges were
collected to coincide with scheduled vaginal sampling.
Blood collection. Blood was collected in clot tubes and
PBMCs were isolated from whole blood using cell preparation
tubes (CPTs). Serum was processed by centrifugation and
aliquoting into cryovials. Cells were isolated from the buffy coat
after centrifugation of the CPTs, washed twice in phosphate
buffered saline (PBS), counted, and then lysed in 70% methanol
before storage in cryovials. All samples were frozen at280uC until
analysis.
Vaginal sample collection. Lavage fluid from a 10 mL
saline CVL was collected into a syringe, transferred into a 15 mL
conical tube, centrifuged, and the supernatant was aliquoted into
cryovials. For the ECC sample, a cervical cytobrush was inserted
into the cervical os, rotated twice through 360 degrees and
removed. The brushes were immersed in PBS with gentle agitation
to remove cells. Cells were washed twice in PBS, counted, lysed
using 70% cold methanol and aliquoted into cryovials. Two
vaginal wall biopsies were taken using 365 mm vaginal biopsy
forceps and placed in a cryovial. All vaginal samples were flash
frozen and stored in a 280uC freezer. At the time of sample
analysis, the biopsies were weighed and homogenized with an
electric mortar and pestle in a 1.5 mL cryovial with 500 mL ice-
cold 70% methanol. Cervicovaginal lavage results were corrected
for estimated average 206dilution of 0.5 mL cervicovaginal fluid
in 10 mL lavage fluid [11].
Rectal fluid collection. Sponges (UltracellH Medical Tech-
nologies, North Stonington, CT) pre-wetted with PBS were
applied to the rectal mucosa through an anoscope for 5 minutes
to adsorb rectal fluid. Sponges were centrifuged and the rectal
fluid removed was stored at 280uC until analysis. TFV
concentrations were not corrected for adsorbed volume, due to
variable estimated sample weights due to evaporative differences
across samples.
Drug Analysis
TFV and TFV diphosphate (TFV-DP) concentrations were
determined by previously described LC-MS/MS methods [12,13]
validated for all matrices by the Johns Hopkins Clinical
Pharmacology Analytical Laboratory. TFV and TFV-DP assays
meet the FDA bioanalysis guidance values of # 615% for
precision and accuracy. (See Table S1 for assay performance.).
Tenofovir. Thawed aliquots of serum, and tissue homoge-
nate, with 13C5-TFV internal standard, were protein precipitated
with methanol. CVL and rectal fluid aliquots with13C5-TFV
underwent solid phase extraction using HLB oasis cartridges. The
supernatants and eluants were collected and dried and reconsti-
tuted in 0.5% acetic acid for analysis. Samples underwent
chromatographic separation using gradient elution with a Zorbax
Eclipse XDB-C18 column, with positive electrospray ionization
(ESI), and detection via multiple reaction monitoring using an LC-
MS/MS system (Waters Acquity UPLC and Agilent 1100 HPLC
Applied Biosystem API4000 mass spectrometer). Calibration
standards for assay ranged from 0.31–1280 ng/ml. (0.25–50 ng/
sample for tissue).
Tenofovir diphosphate (TFV-DP). Cell lysates and tissue
homogenates were analyzed using an indirect assay, which
measures TFV in the sample after isolation of TFV-DP and
enzymatic conversion to TFV essentially. TFV-DP was isolated
from cell lysates on a Waters QMA cartridge (Waters Corporation,
Milford MA) over a salt (KCl) gradient. TFV and TFV
monophosphate (TFV-MP) were eluted from the cartridge under
lower salt concentrations followed by elution of TFV-DP with
application of 1 M KCl to the cartridge. Isolated TFV-DP was
then enzymatically dephosphorylated to TFV via phosphatase
digestion with sweet potato phosphatase with 13C5-TFV internal
standard. Samples were desalted using trifluoroacetic acid and
eluted with 1 mL methanol. The effluent was dried and
reconstituted in 0.5% acetic acid for analysis. Processed samples
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were then chromatographically separated using a reverse phase
Waters BEH C18 column and TFV and IS were ionized using
negative ion mode in electrospray ionization and detected via
multiple reaction monitoring (Waters Acquity UPLC, Applied
Biosystem API5000 mass spectrometer) The assay is linear over
the range of 50.0–1,500 fmol TFV-DP/sample.
Conversions of concentrations to common molar units assume
equivalent density for one gram tissue and one milliliter fluid with
the following cell volume estimates: PBMC, 0.28 pL per cell, ECC
cells, 2.8 pL, which assumed an arbitrary 50:50 mix of stratified
squamous, 4.8 pL, and columnar, 0.8 pL, epithelial cells
[14,15,16,17].
Flow Cytometry
Flow cytometry was performed at the US sites using either
FACSCalibur or Canto flow cytometers (Becton-Dickinson,
Franklin Lakes, NJ) and the following reagents (Becton-Dickinson):
CD38 PE (347687), HLA-DR FITC (347363 [L243]), CD3 PerCP
(347334 [SK7]), CD4 APC (340443), IgG2a FITC (349051), and
IgG1 PE (349043). Results were expressed as percent (using blood
total lymphocyte count) and absolute counts for CD3, CD4 (CD3/
CD4), CD38 (CD3/CD4/CD38), HLA-DR (CD3/CD4/HLA-
DR), and CD38/HLA-DR. Mean fluorescence intensity (MFI)
was assessed for CD38 and HLA-DR.
Data Analysis
Primary TFV PK outcome measures were descriptive concen-
tration-time curves for analytes, peak concentration (Cmax), time to
peak concentration (Tmax), pre-dose concentration (Cpre-dose) based
on individual data for intensive sites and composite concentration
data from research participants at more sparsely sampled non-
intensive sites. Sample size was based on adherence and
acceptability outcomes, not PK outcomes, and is described
elsewhere [18]. For PK outcomes, 72 intensive sampling
participants provide 90% power with 5%, 2-sided alpha error to
detect a 0.38 standard deviation unit difference between regimens
assuming intra-individual correlation. This represents a 14%
difference in Cmax and AUC based on variation in prior reports.
The statistical power of paired comparisons using all 144
participants would be greater. Serum and PBMC concentrations
from US sites were used to estimate Cmax and Tmax using
WinNonlin software (Version 5.0, Pharsight, Inc., Cary, North
Carolina). Concentration prior to an observed clinic dose, Cpre-
dose, was not termed Ctau because participants were instructed to
take their doses before sleep and these samples were collected
during the day at the research sites, prior to the end of the
prescribed dosing interval. Nearly all drug concentrations in all
matrices were skewed upward, thus, log10 transformations of drug
concentrations were used in all models comparing across
treatment regimens. To provide the relative magnitude of paired
differences between routes of dosing, we estimated concentration
ratios. In some cases, these ratios used values between the limit of
detection (LOD, 5 times background) and the LOQ, but only if
the higher of the concentration pair was above the LOQ. We
chose this approach, cognizant of some loss of precision, based on
sensitivity analyses in which exclusion of LOQ values (due to
incalculable ratios with imputed ‘‘0’’ denominator values) or
imputation of an arbitrary non-zero value (LOQ, LOQ/2) for
values below the LOQ resulted in more extreme values or
significantly increased variability. In nearly all cases, using the
actual values between the LOD and LOQ provided ratios between
the values obtained using value imputation.
In order to provide a rough estimate of very recent adherence,
we estimated the time elapsed between the dose prior to the
research clinic visit and the TFV serum sample collected during
that upcoming visit. We used the observed peak serum TFV
concentration as a crude estimate of the peak TFV concentration
associated with the prior dose and estimated the time it would take
for this peak concentration to fall to the observed pre-dose
concentration in the research clinic. With only 8 hours of post-
dose concentration data in our design, we were not confident of
our half-life estimates using traditional PK analyses; so, we used a
range of population-based half-life estimates, 12–17 hours [19,20].
While this approach assumes steady-state conditions, there were
only minor differences in estimated time – less than 10% if we
inflated the peak concentrations to simulate steady-state peak
concentration with 100% daily adherence (slightly longer elapsed
time) and no difference if we assumed no dose accumulation at the
time of the prior dose similar which is comparable to the single
dose peak estimates which can be reasonably estimated by peak-
trough differences with TFV’s rapid absorption. Sparse sampling
PK models are in development to provide more precise model
based estimates, but these estimates bracket timing of recent doses
using population-based data.
Adverse events were compared across treatment regimens using
conditional logistic regression controlling for study period and
randomization sequence. Drug concentrations and Tmax were
compared across drug regimens using linear mixed effects models
controlling for study period and sequence of randomization.
Treatment regimen by period interactions were assessed and were
not statistically significant for any of the outcomes. In addition,
there were no statistically significant period or sequence effects for
any of the outcomes. Correlations between different measures
were assessed using Spearman rank correlation coefficient. Fried-
man’s test was used to test for differences in drug concentrations
over time. All statistical tests were performed using IBM SPSS
Statistics (v. 19, IBM Corporation, Somers, NY) with p value
#0.05 indicating statistical significance.
Results
Study Design and Research Participants
In MTN-001, each research participant was prescribed open
label daily TFV in a series of 3 different regimens, each for a 6-
week period followed by a one-week washout between periods
(Table 1). A different TFV formulation or combination of
formulations was prescribed for each of these periods: oral
300 mg TFV disoproxil fumarate (VireadTM, TDF), vaginal 1%
TFV gel, and a combination of both oral and vaginal formula-
tions. The sequence in which the women were prescribed each
regimen, before crossing over to the next of 3 regimens, was
determined by randomization. At the end of each 6 week period,
blood, peripheral blood mononuclear cells (PBMC), vaginal tissue,
vaginal fluid, and rectal fluid were collected with sample type and
number of samples depending on site capacity. Across the 7
participating clinical sites (3 in Africa and 4 in the US), 408
women were screened, 168 were enrolled and randomized to study
drug, 24 of whom did not complete enough of the study to be
evaluable (adherence data and drug dispensing in all 3 periods)
and were replaced to yield the planned total participation of 144
women (Figure 1). Of these 24 participants who were replaced, 17
refused further participation, 3 completed the study with
incomplete adherence data or drug dispensing in all 3 study
periods, 1 was relocated from study site, 1 was lost to follow-up, 1
had venous access problems, 1 stopped for grade 3 hypophospha-
temia. There were no socio-demographic differences between the
144 evaluable participants and the 24 who were replaced. Half of
research participants (N=72) were enrolled in US sites and half at
Multiple Compartment Distribution of Tenofovir
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the African sites. Research participant characteristics are summa-
rized in Table 2. Each scheduled study visit following enrollment
was attended by 97% to 100% of the participants. Overall,
specimens for PK analysis were collected at 99% of planned study
visits. Study product was put on hold by the study team for
protocol directed reasons (adverse event or treatment of sexually
transmitted infection) for 11 (8%) evaluable research participants
for a median (IQR) duration of 7 (3, 8) days.
Adverse Events
All 3 regimens were well tolerated with mild, transient
symptoms with minimal differences among regimens. The adverse
event profile among the 24 who did not complete the study did not
differ from the study population as a whole. Transient and mild
nausea was more frequent in the oral (15%) and combination
periods (14%) when compared to the vaginal period (3%)
(p,0.001). Headache was also more frequent during the
combination dosing period (8%) compared to vaginal dosing
periods (2%) (p,0.01) with intermediate frequency with oral only
dosing (5%). Hypophosphatemia was the most commonly reported
adverse event, but did not differ in frequency among regimens:
11% vaginal, 15% oral, 15% combination (p.0.05). Between
screening and enrollment, prior to TFV dosing, phosphate was
variable and differed as much as 2 mg/dL.
Figure 1. Accounting of research participants from screening to data analysis.
doi:10.1371/journal.pone.0055013.g001
Table 2. Subject Characteristics.
Characteristic median (IQR) # (%)
Age (years) 29 (25–37)
Weight (kg) 73 (65–88)










Surgical sterilization 22 (15)
IUD 14 (10)
Male partner sterilization 4 (3)
doi:10.1371/journal.pone.0055013.t002
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Drug Time Course
Serum TFV concentrations following observed dosing in clinic
were quantifiable in all participants in all study periods (Table 3).
Pre-dose concentrations, however, were not quantifiable in 20–
38% of participants depending on dosing regimen and were
statistically different when comparing vaginal to either oral or
combination dosing regimens ((p,0.001). Intensive pharmacoki-
netic sampling (vaginal biopsies and more frequent blood
collection) was performed only at the US sites. At intensively
sampled sites during oral and combination dosing study periods,
median (IQR) serum TFV concentrations peaked at 1.0 hour (1.0–
1.2) and 1.0 hour (1.0–1.4), respectively, followed by a log-linear
decline over the next 8 hours (Figure 2A). In the vaginal only study
period, the serum concentration peaked later, at 2.1 hours (1.9–
4.6), followed by a slight decline at the last 8 hour sampling time.
In contrast, the median intracellular PBMC TFV-DP concen-
trations changed only between the pre-dose and 1-hour sample
without further change through 8 hours (Figure 2B). TFV-DP
concentrations were quantifiable in all participants during oral and
combination dosing study periods, but pre-dose TFV-DP concen-
trations were not quantifiable in 34% and 37% of participants in
oral and combination dosing study periods, respectively. The
median concentration-time profile of PBMC TFV-DP in the
vaginal period could not be described since it was quantifiable in
only 7% of participants pre-dose and 17% of participants
following dosing.
For drug concentration in vaginal tissue homogenate, endocer-
vical cytobrush cell lysate, and cervicovaginal lavage fluid, median
concentration at each time was not different among the times from
pre-dose to 8 hours post-dose (p.0.05). By contrast with blood,
oral dosing achieved the lowest drug concentrations in vaginal
tissue, endocervical cytobrush cells, and cervicovaginal lavage
samples where the lower quartile was not quantifiable in any of
these matrices. With vaginal or combination dosing, however,
TFV and TFV-DP was quantifiable in 90 to 95% of tissue
homogenates, 97 to 98% of CVL samples, and 62 to 68% of
endocervical cytobrush cell samples.
Figure 2. Serum TFV and TFV-DP concentration versus time. Serum TFV (panel A) and PBMC TFV-DP (panel B) concentration versus time plots
are shown for the observed 8 hour interval following a dose in clinic according to dosing regimen. Median with asymmetric upper and lower quartiles
is shown. Values are only for the 70 US participants where all 6 PK samples were collected.
doi:10.1371/journal.pone.0055013.g002
Table 3. Summary of TFV and TFV-DP concentrations at all sampled anatomic sites.
Oral Combination Vaginal
Matrix/Moiety/Parameter Units median (IQR) %.LLOQ median (IQR) %.LLOQ median (IQR) %.LLOQ
Serum TFV Cmax ng/mL 332 (257–406) 100 337 (257–447) 100 3.9 (2.2–7.9) 100
Serum TFV Cpre-dose ng/mL 65 (14–103) 80 57 (2–101) 77 0.67 (,0.3–2.09) 62
Serum TFV Tmax hours 1.0 (1.0–1.2) – 1.0 (1.0–1.4) – 2.1 (1.9–4.6) –
PBMC TFV-DP Cmax fmol/10
6 cells 51 (28–74) 99 49 (31–70) 100 ,6 (,6–,6) 17
PBMC TFV-DP Cpre-dose fmol/10
6 cells 17 (3–36) 66 16 (3–34) 63 ,6 (,6–,6) 7
PBMC TFV-DP Tmax hours 4.0 (2.0–6.1) – 4.0 (1.0–6.0) – 3.9 (1.1–6.1) –
Tissue TFV ng/mg 0.15 (,0.15–0.27) 50 104 (40–268) 96 113 (27–265) 94
Tissue TFV-DP fmol/mg ,25 (,25–,25) 19 2,464 (917–6,112) 96 1,807 (591–5,860) 90
Cervicovaginal lavage ng/mL 5,380 (,6–201,560) 59 1.66106 (0.5610–6.56106) 98 3.16106 (0.66106–8.16106) 97
Endocervical Cytobrush fmol/106 cells ,130 (,130–,130) 18 903 (159–4,283) 62 1,181 (147–5,418) 68
Rectal Sponge ng/sponge 20 (7–404) 83 576 (140–2887) 100 119 (53–2150) 100
Data from end-of-period visit showing median (interquartile range) by dosing regimen in common concentration units. Serum TFV Cpre-dose, PBMC TFV-DP Cpre-dose, and
cervicovaginal lavage include African clinical sites; other parameters are calculable only for US clinical sites. Rectal sponges are only from one US site. For values below
the LLOQ, [median LLOQ] is shown. Cervicovaginal lavage results were corrected for estimated average 206dilution of 0.5 mL cervicovaginal fluid in 10 mL lavage
fluid [11].
doi:10.1371/journal.pone.0055013.t003
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Because there were no temporal trends in locations other than
blood and each subject provided only one sample from these
locations at each end-of-period visit, results from tissue and
cervicovaginal lavage fluid are summarized as median of values
from all times in Table 3. Drug concentrations for each study
period are compared across all anatomic sites using common
molar units to allow comparison of TFV to TFV-DP in Figure 3.
Because each daily dose was to be taken at the hour of sleep and
clinic visits usually occurred in the morning, Cpre-dose is not a true
trough (Ctau), but is a sample between Cmax and Ctau. The Cpre-dose
sample occurs 13 (10–14) hours (median [IQR]) following the
prior dose according to subject self-report – an interval consistent
with the protocol. Similarly, Cmax is also potentially different than
a true steady-state Cmax since it follows a short dosing interval.
Assuming excellent adherence and steady-state, both Cpre-dose and
Cmax will be overestimates. Poor adherence, however, would have
an opposite, depressing effect on concentrations. Pre-dose
concentrations are influenced both by individual pharmacokinetics
and by the timing of prior doses with progressively greater
influence of the more recent doses. We estimate that the median
interval of time between the oral dose taken prior to the research
visit blood collection was 1.2 to 1.7 days; the interval for the prior
vaginal dose was between 1.3 to 1.8 days.
Rectal Fluid
Rectal fluid was collected at only one US site. Rectal sponge
TFV concentrations were quantifiable in 10 of 12 participants
(83%) in the oral dosing study period and in all participants in the
combination and vaginal dosing study periods. Median concen-
tration between combination and oral dosing study periods were
statistically significantly different (p = 0.008), as were mean
concentrations between the vaginal and oral study periods
(p#0.03) (Table 3).
Dosing Route Comparisons
Using linear mixed effect models controlling for study period
and randomization sequence after log10 transformations of the
end-of-period concentration data, vaginal only dosing was
different than oral only dosing for all matrices tested (all
p,0.001, except rectal sponge p= 0.03). Combination dosing
was only different compared to vaginal only dosing for serum and
PBMC’s (p,0.001) and compared to oral only dosing for tissue,
CVL, endocervical cytobrush, and rectal (all p,0.001, except
rectal p = 0.008). The relative magnitude of the dose regimen
relationships across matrices via paired individual ratios are
provided in Table 4. The paired individual oral:combination
concentration ratios for serum TFV and PBMC TFV-DP were
unity while the oral and combination regimens achieved 58 and 56
fold greater TFV serum concentrations, respectively, compared to
vaginal dosing. The PBMC ratio for oral and combination
compared to vaginal study periods was lower, 17 and 15,
respectively, and far fewer pairs were available for these ratios
given the low frequency of quantifiable vaginal dosing PBMC
concentrations. In vaginal tissue samples, the picture was reversed
with vaginal:combination dosing ratios near unity for TFV and
TFV-DP. The median combination and vaginal dosing concen-
trations were 635–797 times greater for TFV and 130–173 times
greater for TFV-DP when compared to oral-only dosing (Table 4).
Figure 3. Boxplots of TFV and TFV-DP concentrations by anatomic site. Side-by-side boxplots of end-of-period visit data for all participants
by anatomic site and dosing regimen are shown. Each box indicates the interquartile range with center bar as median and whiskers 1.5 times the
quartile. *Lower quartile (LQ) is below the limit of quantitation (LOQ), only median and above are shown. **Median is below LOQ, so the median of
values above the LOQ are shown as a single bar. X-axis key: anatomic location, PBMC peripheral blood mononuclear cells, CVL cervicovaginal lavage,
ECC endocervical cytobrush; drug moiety, TFV tenofovir, TFV-DP tenofovir diphosphate; sample timing, Cmax peak concentration following dose at
clinic visit, Cpre-dose concentration prior to dose at clinic visit, Call pools values from all participants regardless of scheduled time relative to dose.
doi:10.1371/journal.pone.0055013.g003
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The vaginal:oral dosing ratios for CVL were not as large. We
corrected CVL results for an estimated 20-fold dilution by the
10 mL lavage fluid added to 0.5 mL native cervicovaginal fluid
[11], but this overestimates dilutional effects when there is up to
3.5 mL residual TFV gel for which a smaller dilution correction is
needed. Complete pairs were available for only 58 of 144 (40%)
participants to calculate vaginal:oral endocervical cytobrush cell
ratios.
Phosphorylation Ratios
The ratio of TFV to TFV-DP in blood and tissue sources were
all greater than unity with the lowest ratio seen in the pre-dose
serum TFV to PBMC TFV-DP ratio, with median values of 2.5
(oral only) and 2.9 (combination) (Table 5). Blood ratios were
sensitive to timing given the unsynchronized concentration-time
pattern of serum TFV and PBMC TFV-DP. Also, it should be
noted that these PBMC assessments do not address the TFV
monophosphate moiety which is present, but unmeasured here.
Higher TFV:TFV-DP ratios were observed in tissue. Presumably,
intracellular TFV-DP was diluted by extracellular constituents and
cell volume after tissue homogenization whereas assessments in
PBMC were adjusted only for lymphocyte cell volume. Because
CVL and ECC concentration values were subject to differential
lavage dilution based on dosing regimen and uncertain epithelial
cell volume, respectively, the CVL:ECC TFV:TFV-DP ratio was
not estimated.
Flow Cytometry
Initial median (IQR) values for PBMC surface markers were
absolute lymphocyte count 2209 (1827, 2722), %CD3 77 (74, 81),
%CD4 49 (44, 54), %CD38 66 (51, 78), %HLA-DR 5 (3, 7),
%CD38/HLA-DR 3 (2, 4). There were no differences among the
3 study periods for any cell surface marker (p.0.1). When assessed
within each dosing regimen, mean fluorescence intensity values for
both CD38 and HLA-DR on PBMCs were negatively correlated
with TFV-DP tissue concentrations (all rs.0.34, all p,0.001), but
these surface markers did not correlate with TFV-DP concentra-
tion in PBMC or endocervical cytobrush cells. There was no
correlation of percent or absolute number of either CD4 or CD8
with TFV-DP in any anatomic site by any route of dosing.
Discussion
Our cross-over design allows for the direct paired comparisons
of TFV PK within individuals in multiple anatomic sites, avoiding
inter-individual variability. The most significant finding is the
greater than 100-fold higher concentration of the active TFV
moiety, TFV-DP, in vaginal tissue homogenates with vaginal
dosing when compared to an oral regimen alone. Conversely,
systemic exposure (serum TFV) after vaginal dosing was at least
56-fold lower than after oral dosing regimens. This difference in
systemic exposure based on route of dosing may have been the
cause of the greater frequency of nausea, diarrhea, and headache
with oral regimens, though the gastrointestinal symptoms may
Table 4. Concentration ratios between dosing period by anatomic location.
Vaginal:Oral Vaginal:Combination Combination:Oral
PK Parameter Maximum N N Median (IQR) N Median (IQR) N Median (IQR)
Serum TFV 560 450 0.017 (0.008–0.034) 449 0.018 (0.007–0.035) 462 1.0 (0.8–1.3)
PBMC TFV-DP 560 260 0.06 (0.02–0.21) 251 0.07 (0.02–0.20) 452 1.0 (0.6–1.7)
Tissue TFV 70 63 797 (162–1623) 63 1.1 (0.3–3.3) 65 635 (179–1,474)
Tissue TFV-DP 70 49 130 (19–425) 64 0.8 (0.3–2.1) 50 173 (37–424)
CVL TFV 140 52 51 (3–365) 93 1.1 (0.6–2.8) 54 79 (5–391)
CB TFV-DP 70 28 2.2 (0.8–16.6) 54 0.9 (0.4–4.2) 33 3.6 (0.4–11.8)
Rectal TFV 12 10 6.1 (0.4–15.9) 12 0.3 (0.2–4.0) 10 3.1 (1.9–52.8)
Pairs are included if at least one is above the limit of assay quantitation and the other is above the limit of assay detection. Other pairs are excluded. Serum and PBMC
ratios are based on pooled values for data pairs from all times with research participants contributing more than one pair.
doi:10.1371/journal.pone.0055013.t004
Table 5. Ratio of unphosphorylated TFV to phosphorylated TFV-DP by anatomic sampling sites.
Oral Combination Vaginal
Molar Ratio Maximum N N Median (IQR) N Median (IQR) N Median (IQR)
Serum TFV/PBMC TFV-DP Cmax 70 65 5.9 (3.6, 10.1) 69 6.2 (4.1, 9) *10 NA
Serum TFV/PBMC TFV-DP Cpre-dose 144 89 2.5 (1.6, 4.5) 104 2.9 (1.7, 5.3) *6 NA
Serum TFVall/PBMC TFV-DPall 560 475 4.8 (2.6, 9.5) 479 4.2 (2.6, 9) 245 1.2 (0.4, 4.6)
Tissue TFV/Tissue TFV-DP 70 27 48 (22, 130) 67 170 (63, 418) 64 207 (84, 485)
Pairs are included if at least one value in the pair is above the limit of assay quantitation and the other is above the limit of assay detection. ‘‘N’’ is the number of pairs
available meeting the inclusion criteria above. ‘‘Maximum N’’ is the number of possible pairs if all subjects at all visits provided a sample. Cmax only includes US
participants where multiple serum samples were available; the pair is defined by serum Cmax matched with the corresponding PBMC TFV-DP concentration which is not
necessarily peak TFV-DP after the same dose. Subscript ‘‘all’’ indicates that all PBMC-Serum pairs from each sample times are included, with participants contributing
multiple pairs. All p,0.001 Wilcoxon signed rank test for TFV fmol/gm vs. TFV-DP fmol/gm. *Insufficient samples above the limit of assay quantitation and detection to
estimate reliable medians given the inevaluable excluded pairs.
doi:10.1371/journal.pone.0055013.t005
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have been due to local gastrointestinal effects in oral dosing
regimens. The large systemic exposure differences, yet with similar
rates of hypophosphatemia with both oral and vaginal regimens,
argues against a significant dose-dependent relationship between
TFV and hypophosphatemia.
The temporal patterns of drug concentration we observed are
consistent with expectations based on the relatively shorter 12–17
hour serum half-life of TFV [19,20], resulting in large concentra-
tion undulations over 8 hours, and a far longer half-life of several
days for TFV-DP [21,22], resulting in essentially flat concentra-
tions over an 8 hour interval. One methodological concern in
topical dosing studies is contamination of tissue biopsies by luminal
drug retained on the biopsy despite washing. Our results suggest
that this effect is minor, at best, given the relatively high TFV-DP
concentration (which requires cellular uptake for phosphorylation)
in vaginal biopsies.
The amount of TFV extracted from rectal sponges was 3 times
higher with combination dosing when compared to oral dosing,
though vaginal dosing was not statistically different from oral or
combination dosing. This may result from an additive effect of oral
and vaginal dosing not seen in any other anatomic site, but may
also have resulted from assay variability due to the collection
method and should be cautiously interpreted. Use of an internal
standard in the rectal sponge would greatly improve the accuracy
of this sampling method. Without this, heterogeneity of both fluid
volume adsorbed onto the sponge and subsequent evaporative
losses prior to sample freezing may introduce significant and
unmeasured variation which prevents accurate estimates of
concentration. Regardless, the finding of greater or similar rectal
fluid concentrations after vaginal dosing alone compared to oral
dosing suggests that vaginal dosing may also provide some level of
protection from receptive anal intercourse. A similar vaginal to
rectal drug migration has been reported by Nuttall, et al., in
macaques where rectal fluid TFV concentrations were 1 to 2 log10
lower than vaginal fluid TFV concentrations following vaginal
dosing [23].
The most notable result of the study is the 100-fold greater
TFV-DP concentrations in vaginal tissue associated with vaginal
dosing. This more precise estimate from our cross-over design
confirms what can be inferred from combining results of separate
oral dosing studies [24] with vaginal dosing studies [25]. Related to
this, combination dosing conferred no concentration benefits in
vaginal tissues. Considered in isolation, this finding of higher
vaginal tissue concentrations with vaginal dosing anticipates both
an increased level of protection from acquisition of HIV infection
and a regimen more tolerant of missed doses or planned
intermittent dosing with vaginal dosing compared to oral dosing.
This assumes: (1) drug concentration in vaginal tissue is relevant to
HIV protection; (2) tissue drug concentrations with oral dosing are
not 100 times greater than needed for HIV protection (beyond the
plateau on the concentration-response curve); and (3) no negative
effect on HIV transmission at higher drug concentrations or
associated with the vaginal gel vehicle.
The modest (CAPRISA 004) or absent (VOICE) efficacy seen in
the TFV gel studies, despite vaginal tissue levels expected (based
on MTN-001) to be far higher than in the very successful Partner’s
PrEP and TDF2 studies, suggests that efficacy is more complex
than would be predicted by vaginal tissue concentration alone
[1,3,4,7]. The disparate oral v. topical trial results, despite vaginal
tissue concentration expectations, may be evidence that vaginal
tissue concentrations are not, in fact, the critical site of ARV action
in PrEP. Systemic PBMC or draining cervicovaginal lymph nodes,
each of which would have higher TFV-DP concentrations with
oral dosing, may be more important. This alone, however, cannot
explain the higher efficacy in CAPRISA 004 compared to
VOICE.
Adherence is a powerful explanatory variable among oral
studies given the enhanced relative risk reduction when drug can
be measured in the blood (Partner’s PrEP, iPrEX) and absence of
efficacy when concentrations are lower (FEM-PrEP) [5,8,26]. If
vaginal tissue TFV-DP concentration is the critical site of action
for the preventive efficacy of TFV, then adherence alone is very
unlikely to explain low (or no) vaginal gel efficacy in light of the
100-fold greater vaginal tissue concentration advantage of vaginal
compared to oral dosing. For example, if poor adherence is to
explain the lower topical dosing efficacy (VOICE and CAPRISA
004) when compared to Partner’s PrEP and TDF2, adherence
would have to be sufficiently worse in the topical dosing studies
that vaginal tissue concentrations fall sufficiently far to negate the
greater than 100-fold vaginal tissue TFV-DP advantage associated
with vaginal dosing and then fall even further to lose most or all of
beneficial effects of oral dosing seen in Partners PrEP and TDF2.
To put this adherence difference in temporal terms, consider the
half-life of elimination of TFV-DP from vaginal tissue. The
terminal half-life of TFV-DP after a single oral dose as measured
in vaginal tissue homogenates over two weeks of sampling is
estimated at 53 hours [27]. We also estimated a 90 hour half-life
using mean vaginal tissue mean TFV-DP data reported in a single
oral TDF/FTC dose study [28]. Using these half-life estimates of
53 or 90 hours, the women receiving TFV gel in our study could
stop all dosing for more than 2 weeks before their vaginal tissue
TFV-DP concentration falls to the concentrations achieved in the
oral only dosing arm in the same women [27,28]. Yet, we see
nothing like this kind of low adherence with vaginal dosing – our
crude estimates are between 3.2 and 5.2 doses per week.
Therefore, there must be unmeasured variables at work with
topical TFV that negate the vaginal concentration-dependent
protection of tenofovir demonstrated among oral TFV PrEP
studies. Plausible explanations for this protection-negating, possi-
bly HIV-enhancing, effect include tissue toxicity from either
concentration-dependent TFV or TFV-DP effects or dose
frequency-dependent gel vehicle effects. Although TFV 1% gel
has been found to be safe and well tolerated in women, our
hypothesized negative effects could be either beneath the level of
sensitivity or beyond the scope of the safety measures employed in
large clinical trials. To impute non-drug related HIV enhancing
effects as the cause of lower than expected efficacy in topical
studies – increased frequency of anal intercourse, elevated partner
viral load, noxious environmental or para-sexual behaviors,
increased prevalence of sexually transmitted infections, higher
systemic innate immune activation [29] – requires three condi-
tions. First, the factor(s) must be more prevalent in the poor
efficacy topical studies than the high efficacy oral studies. Second,
the factor(s) must have a disproportionately high impact on
narrowing relative risk reduction in poor efficacy topical PrEP
studies compared to high efficacy oral studies. Third, these factors
must combine for a greater magnitude of effect than the greater
than 100-fold TFV-DP tissue concentration advantage with
topical dosing. The tissue concentration differences between oral
and vaginal dosing can only partially be mitigated by poor
adherence as we argue above. Cross-study analyses of measured
variables and smaller hypothesis testing studies to assess unmea-
sured, but biologically plausible, variables are needed to under-
stand the interaction of pharmacologic with non-pharmacologic
variables. Identification of these variables is essential to improving
future PrEP development.
Poor adherence in our study could reduce observed concentra-
tions and increase variability. We had clear evidence of poor
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adherence in many subjects which we detailed in another report
(Minnis, et al) [10]. However, greater than 60% of subjects had
evidence of consistent daily dosing based on comparison of
individual drug concentrations at study visits to expected
concentrations based on observations in observed dosing studies.
Therefore, since we reported medians to summarize our data,
these point estimates were largely resistant to the downward
adherence bias. In addition, the magnitude of the differences
between regimens was so large that the skewed distribution due to
adherence bias in the lower tail had little effect.
It is unclear why we detected a correlation between PBMC
surface marker with TFV-DP concentration in vaginal tissue, but
not PBMC on whose surface the increased activation markers
were detected. It is possible that (unmeasured) vaginal tissue
activation markers had an even greater correlation with tissue
TFV-DP concentration and a modest correlation with PBMC
markers, but we did not extract cells from vaginal tissue to test
these correlations directly. Three separate in vitro studies indicate
complex intracellular TFV-DP effects of PHA (+ IL-2) stimulation:
no TFV-DP concentration difference in resting versus PHA/IL-2
stimulated PBMCs [30]; 2-fold higher TFV-DP concentration in
resting compared to PHA/IL-2 stimulated CEM cells after 6 hours
in culture, but no different after 24 hours in culture [31]; 3-fold
higher TFV-DP concentration in resting compared to PHA
stimulated PBMCs which persisted over 24 hours [32]. In contrast,
dATP increases from 3-fold [30] to 10-fold [33] with PHA6IL-2
stimulation which suggests that increased cellular activation would
shift the dATP/TFV-DP ratio by modifying the numerator and
denominator in directions unfavorable to antiviral effect. In
general, the direction of the correlation between cell activation
(indicated by CD38 and HLA-DR expression) with decreasing
tissue TFV-DP concentration in our clinical study is consistent
with 2 of 3 in vitro studies.
Limitations to our study were several and point out the
difficulties in sampling and comparing findings in these complex
and varied anatomic spaces. Due to the destructive sampling
(CVL, endocervical cytobrush) or logistical complexity (biopsies),
we used a sparse sampling approach for some anatomic and
geographic sites. Population PK modeling is underway to best
incorporate this data to understand the temporal and spatial
relationships of drug in multiple anatomic compartments. The
short, variable, and uncertain (self-reported) dosing interval before
the clinic dose introduced additional noise in drug concentration
assessments, but the impact was minimal for all but serum
concentration data due to the relatively long half-life and flat
concentration-time profile in other sites. Our CVL samples were
based on dilution-adjusted TFV concentrations which bring all of
the concentration values closer to their original state. However,
this crude adjustment doesn’t account for variations in native
cervicovaginal fluid volume and results in significant underesti-
mates in subjects sampled post-gel dose in vaginal dosing periods
due to residual TFV gel volume. An internal standard, like lithium
[11,34,35], to correct for lavage dilution or a validated direct
sampling method (syringe, sponge, other adsorbent material)
would improve these estimates. Our conversion of intracellular
TFV-DP per cell concentrations to molar per volume concentra-
tions helpfully enables comparisons of parent to phosphorylated
drug moieties in adjacent spaces or to TFV-DP in different spaces.
However, these conversions are not based on our direct assessment
of cell volume or type (PBMC subsets, columnar or squamous
epithelial cells), but on reasoned assumptions applying previous
reports and best guesses. Finally, assessment of TFV-DP in CD4+
T cells extracted from vaginal tissue biopsies would have been
preferred over tissue homogenates to provide both a more relevant
cell-specific intracellular TFV-DP concentration and to avoid the
dilutional effects of extracellular components in tissue homoge-
nates. Nonetheless, if tissue homogenate concentrations are shown
to have a systematic relationship to tissue CD4+ T cell TFV-DP,
tissue homogenate TFV-DP data will be useful. These limitations
warrant cautious application of our comparisons of parent to
phosphorylated moiety within a compartment, oral to topical
dosing in some compartments (CVL), and comparison between
compartments all of which require assumptions based on limited
data which leave ample room for future progress.
Conclusion
In healthy women, daily dosing of tenofovir 1% gel (40 mg)
achieves substantially lower (56-fold) systemic exposure of
tenofovir compared to daily oral dosing of tenofovir disoproxil
fumarate (VireadTM). Rectal fluid concentrations of tenofovir were
greater after vaginal dosing than oral dosing raising the potential
that a vaginal dosing route might provide some level of protection
from receptive anal intercourse, though this remains to be studied.
When compared to daily oral dosing, vaginal dosing achieved
more than 130 times greater vaginal tissue concentrations of active
drug (tenofovir diphosphate), leading to the expectation that
vaginal TFV dosing should achieve greater protective efficacy than
oral TFV dosing, even allowing for very poor adherence. Because
this concentration advantage has not been seen in the serocon-
version outcomes of two randomized clinical trials (CAPRISA 004
and VOICE), it raises concern that factors beyond TFV’s antiviral
effect may substantially reduce PrEP efficacy when dosed topically.
This discordance between drug concentration and expected
outcome warrants further investigation to better understand
TFV and other antiretroviral approaches to topical HIV
prevention.
Supporting Information
Table S1 Summary of TFV and TFV-DP assay perfor-
mance characteristics by biological matrix.
(DOCX)
Protocol S1 Trial protocol.
(PDF)
Checklist S1 CONSORT checklist.
(DOCX)
Acknowledgments
We wish to acknowledge the significant contribution to this research from
the research participants without whom the work is not possible. In
addition, the authors wish to specifically acknowledge the contributions of
the MTN-001 Study Group with special note of: Nicole Anders, Dawn
Antosh, Jane Baum, Katherine Bunge, Martha Cavallo, Jianmeng Chen,
Mitchell D. Creinin, Brodie Daniels, Moira S. Flynn, Angelina Gangestad,
Faye E. Howard, Sherri Johnson, Samuel Kabwigu, Betty Kamira, Flavia
M. Kiweewa, Nicolette A. Louissaint, Teresa Parsons, Arendevi Panther,
Carol Priest, Sharon Riddler, and Shay J. Warren.
Author Contributions
Conceived and designed the experiments: CWH BAC VG JJ CN RS LST
AMM KG BAR. Performed the experiments: CWH BAC VG CH JJ CN
RS LST KP AMM SG KG BAR NNB. Analyzed the data: CWH KP
AMM SG BAR NNB. Wrote the paper: CWH BAC VG CH JJ CN RS
LST KP AMM SG KG BAR NNB.
Multiple Compartment Distribution of Tenofovir
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e55013
References
1. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al.
(2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for
the prevention of HIV infection in women. Science 329: 1168–1174.
2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010)
Preexposure chemoprophylaxis for HIV prevention in men who have sex with
men. N Engl J Med 363: 2587–2599.
3. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012)
Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and
Women. N Engl J Med.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012)
Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in
Botswana. N Engl J Med.
5. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012)
Preexposure Prophylaxis for HIV Infection among African Women.
N Engl J Med.
6. MTN. (2011) MTN Statement on Decision to Discontinue Use of Oral
Tenofovir Tablets in VOICE, a Major HIV Prevention Study in Women. In:
Network MT, editor. Web site article.
7. MTN. (2011) MTN Statement on Decision to Discontinue Use of Tenofovir Gel
in VOICE, a Major HIV Prevention Study in Women.
8. Donnell D, Baeten J, Hendrix CW, Bumpus N, Bangsberg D, et al. (2012)
Detectable plasma levels over time in a pre-exposure prophylaxis clinical trial:
the Partners PrEP Study. Microbicides 2012. Sydney.
9. Karim SS, Kashuba AD, Werner L, Karim QA (2011) Drug concentrations
after topical and oral antiretroviral pre-exposure prophylaxis: implications for
HIV prevention in women. Lancet 378: 279–281.
10. Minnis AM, Gandham S, Richardson BA, Guddera V, Chen BA, et al. (2012
(In Press)) Adherence and acceptability in MTN 001: A randomized cross-over
trial of daily oral and topical tenofovir for HIV prevention in women. AIDS
Behav.
11. Mitchell C, Paul K, Agnew K, Gaussman R, Coombs RW, et al. (2011)
Estimating volume of cervicovaginal secretions in cervicovaginal lavage fluid
collected for measurement of genital HIV-1 RNA levels in women. J Clin
Microbiol 49: 735–736.
12. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, et al. (2011) A
randomized trial to assess anti-HIV activity in female genital tract secretions and
soluble mucosal immunity following application of 1% tenofovir gel. PLoS One
6: e16475.
13. King T, Bushman L, Kiser J, Anderson PL, Ray M, et al. (2006) Liquid
chromatography-tandem mass spectrometric determination of tenofovir-diphos-
phate in human peripheral blood mononuclear cells. J Chromatogr B Analyt
Technol Biomed Life Sci 843: 147–156.
14. Simiele M, D’Avolio A, Baietto L, Siccardi M, Sciandra M, et al. (2011)
Evaluation of the mean corpuscular volume of peripheral blood mononuclear
cells of HIV patients by a coulter counter to determine intracellular drug
concentrations. Antimicrob Agents Chemother 55: 2976–2978.
15. Reagan JW, Hamonic MJ, Wentz WB (1957) Analytical study of the cells in
cervical squamous-cell cancer. Lab Invest 6: 241–250.
16. Reagan JW, Bell BA, Neuman JL, Scott RB, Patten SF (1961) Dysplasia in the
uterine cervix during pregnancy: an analytical study of the cells. Acta Cytol 5:
17–29.
17. Blaskewicz CD, Pudney J, Anderson DJ (2011) Structure and function of
intercellular junctions in human cervical and vaginal mucosal epithelia. Biol
Reprod 85: 97–104.
18. Hendrix CW, Minnis A, Guddera V, Riddler S, Salata R, et al. (2011) MTN-
001: A Phase 2 Cross-Over Study of Daily Oral and Vaginal Tenofovir in
Healthy, Sexually Active Women Results in Significantly Different Product
Acceptability and Vaginal Tissue Drug Concentrations. 18th Conference on
Retroviruses and Opportunistic Infections February 27-March 2, 2011 Boston,
MA (Abstract 35LB). Boston, MA.
19. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, et al. (2001)
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of
tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
Antimicrob Agents Chemother 45: 2733–2739.
20. Kearney BP, Flaherty JF, Shah J (2004) Tenofovir disoproxil fumarate: clinical
pharmacology and pharmacokinetics. Clin Pharmacokinet 43: 595–612.
21. Hawkins T, Veikley W, St Claire RL, 3rd, Guyer B, Clark N, et al. (2005)
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate,
and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
J Acquir Immune Defic Syndr 39: 406–411.
22. Pruvost A, Negredo E, Theodoro F, Puig J, Levi M, et al. (2009) Pilot
pharmacokinetic study of human immunodeficiency virus-infected patients
receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and
intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-
ritonavir. Antimicrob Agents Chemother 53: 1937–1943.
23. Nuttall J, Kashuba A, Wang R, White N, Allen P, et al. (2012) Pharmacokinetics
of tenofovir following intravaginal and intrarectal administration of tenofovir gel
to rhesus macaques. Antimicrob Agents Chemother 56: 103–109.
24. Dumond JB, Yeh RF, Patterson KB, Corbett AH, Jung BH, et al. (2007)
Antiretroviral drug exposure in the female genital tract: implications for oral pre-
and post-exposure prophylaxis. AIDS 21: 1899–1907.
25. Schwartz JL, Rountree W, Kashuba AD, Brache V, Creinin MD, et al. (2011) A
multi-compartment, single and multiple dose pharmacokinetic study of the
vaginal candidate microbicide 1% tenofovir gel. PLoS One 6: e25974.
26. Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, et al. (2011)
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV
infection. J Antimicrob Chemother 66: 240–250.
27. Louissaint N, Cao Y, Tannenbaum S, Skipper P, Liberman R, et al. (2011)
Single dose 14C-Tenofovir Distribution into Blood, Colon, and Vagina in
Healthy Volunteers. Keystone Symposium: Protection from HIV: Targeted
Intervention Strategies. Whistler, British Columbia, Canada.
28. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, et al. (2011)
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for
prevention of HIV-1 transmission. Sci Transl Med 3: 112re114.
29. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, et al.
(2012) Innate Immune Activation Enhances HIV Acquisition in Women,
Diminishing the Effectiveness of Tenofovir Microbicide Gel. J Infect Dis 206:
993–1001.
30. Robbins BL, Wilcox CK, Fridland A, Rodman JH (2003) Metabolism of
tenofovir and didanosine in quiescent or stimulated human peripheral blood
mononuclear cells. Pharmacotherapy 23: 695–701.
31. Balzarini J, Van Herrewege Y, Vanham G (2002) Metabolic activation of
nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and
Langerhans cells. AIDS 16: 2159–2163.
32. Robbins BL, Srinivas RV, Kim C, Bischofberger N, Fridland A (1998) Anti-
human immunodeficiency virus activity and cellular metabolism of a potential
prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypro-
pyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob
Agents Chemother 42: 612–617.
33. Gao WY, Agbaria R, Driscoll JS, Mitsuya H (1994) Divergent anti-human
immunodeficiency virus activity and anabolic phosphorylation of 29,39-
dideoxynucleoside analogs in resting and activated human cells. J Biol Chem
269: 12633–12638.
34. Mohamed AS, Becquart P, Hocini H, Metais P, Kazatchkine M, et al. (1997)
Dilution assessment of cervicovaginal secretions collected by vaginal washing to
evaluate mucosal shedding of free human immunodeficiency virus. Clinical and
Diagnostic Laboratory Immunology 4: 624–626.
35. Belec L, Meillet D, Levy M, Georges A, Tevi-Benissan C, et al. (1995) Dilution
assessment of cervicovaginal secretions obtained by vaginal washing for
immunological assays. Clin Diagn Lab Immunol 2: 57–61.
Multiple Compartment Distribution of Tenofovir
PLOS ONE | www.plosone.org 11 January 2013 | Volume 8 | Issue 1 | e55013
